2017 Fiscal Year Final Research Report
Individualized therapy for primary lung cancer: BIM polymorphism as a stratification factor
| Project/Area Number |
15K09195
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KABURAKI kyouhei 東邦大学, 医学部, 助教 (00439944)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | BIM遺伝子多型 / PD-L1 / BIMγ |
|---|
| Outline of Final Research Achievements |
Expression of BIM protein in primary lung tumors in EGFR-mutated lung adenocarcinoma did not correlate with presence of BIM polymorphism, which was noted in about half of patients. In all patients with BIM polymorphism, BIMγ was expressed in the tumor area or non-tumor area. Moreover, the frequency was significantly higher, and the relative quantification value was nonsignificantly higher, than in patients without BIM polymorphism. Progression-free survival for gefitinib was significantly shorter in patients with positive BIMγ expression, which suggests that BIMγ expression is associated with poor prognosis in patients with EGFR-mutated lung adenocarcinoma receiving gefitinib. In addition, BIM expression in the tumor area significantly positively correlated with PD-L1 expression.
|
| Free Research Field |
呼吸器内科学
|
